Geron (GERN) reported a Q3 loss Thursday of $0.04 per diluted share, narrowing from a loss of $0.08 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.09.

Revenue for the quarter ended Sept. 30 was $28.3 million, up from $164,000 a year earlier.

Analysts polled by Capital IQ expected $19 million.

For fiscal 2024, the company said it expects total operating expenses of about $260 million to $270 million.

The company also said its existing cash, cash equivalents and marketable securities, together with anticipated revenue from US sales of Rytelo, will be sufficient to fund its projected operating requirements for at least the next 12 months.

Price: 4.43, Change: +0.16, Percent Change: +3.63